Stada’s owners improve offer
Stada Arzneimittel’s controlling shareholders, Bain Capital and Cinven, have made an improved €81.83 (US$94.38) per share offer to minority shareholders as they seek to take full control of the German generics and OTC specialist. The offer is a tenth higher than the previous €74.40 per share bid that failed to attract holders of 35% of Stada shares not currently held by their Nidda Healthcare vehicle (Generics bulletin, 11 May 2018, page 6).
You may also be interested in...
Nidda Healthcare, the investment vehicle controlled by Bain Capital and Cinven, has decided on a share price for the final squeeze-out of Stada’s remaining minority shareholders.
ASTM International is proposing a new standard that will provide a cleaning agent formula for removing dried blood from stainless steel medical devices.
Executive appointments at MyoKardia, Scancell Holdings and Sutro Biopharma